The National Histology Conference was a collaborative endeavour this year as hosts Histology Group of Victoria worked together with histology groups from Queensland, New South Wales and South Australia to create a true national conference. Held in Hobart, Tasmania, it is the first instance of the conference being held in a state without an organised […]
The National Cancer Center Japan, JVCKENWOOD Corporation, Sysmex Corporation and Daiichi Sankyo Company Limited announced today that they have commenced collaborative research with the aim of raising the quality of cancer diagnosis and treatment. The collaborative research will target exosome, a microparticle released from tissues.
The Dow Jones Sustainability Indexes are developed through collaboration between S&P Dow Jones Indices of the United States and Robeco SAM, a Swiss research specialist in the area of socially responsible investment. This year Sysmex has been selected for inclusion in the DJSI World for the second consecutive year.
Creating a System for Operating Mobile Pharmacies as a Disaster Response Measure – Sysmex Corporation, the Hyogo Pharmaceutical Society and Shinkai Transport Systems, Ltd. announce the signing of an agreement to cooperate on disaster relief activities, aimed at operating mobile pharmacies in times of disaster.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has opened a new R&D facility within its Kawasaki Innovation Gateway at SKYFRONT in the city of Kawasaki, Kanagawa Prefecture, to pursue R&D in bioinformatics, a key technology toward the realisation of personalised medicine.
In order to continue supporting the initiatives of the GHIT Fund, which aims to assist in the application of Japanese technological innovation to healthcare in developing countries, we will be extending our provision of donations for a five-year period from 2018. By participating in the GHIT Fund, we will move forward with initiatives to develop and provide new reagents for infectious diseases in the aim of eradicating infectious diseases in developing countries.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement with Oxford Gene Technology IP Limited (HQ: Oxfordshire county, United Kingdom; CEO: Michael Evans; “OGT”) to acquire all shares in OGT (the “Acquisition”). Through this move, Sysmex aims to obtain OGT’s business and expertise in the cytogenetics1 domain and its reagent development capabilities used in next-generation sequencers (NGSs)2, thereby reinforcing its base in the life science business.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has received the Invention Award in the National Commendation for Invention1, sponsored by the Japan Institute of Invention and Innovation, for its hematology analyzers that enables the rapid evaluation of the effects of administering iron preparations. The award ceremony is scheduled to be held in Tokyo on Monday, June 12.
Sysmex New Zealand has appointed a new senior management team. James Webster has stepped aside as Sysmex New Zealand CEO to focus his full attention on his role as Sysmex Australia CEO. Assuming the position of Sysmex New Zealand CEO is Arjit Bhana, formerly the company’s General Manager. James Webster said “I may have moved […]
The following article was written by Kate McDonald and published in Pulse+IT on 5 April 2017. CareConnect consolidates on one site as GPs get single sign-on to TestSafe General practitioners in NZ’s Northern region now have single sign-on access to the TestSafe clinical data repository through the My Practice and Medtech32 practice management systems, allowing […]